Neurokinin1 receptor antagonists as potential antidepressants

S. C. Stout, M. J. Owens, Charles Nemeroff

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin1 (NK1). Although originally studied as potential analgesic compounds, recent evidence suggests that NK1 receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct from all existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK1 receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK1 receptor antagonists have served as an impetus for much needed, basic research in this field.

Original languageEnglish
Pages (from-to)877-906
Number of pages30
JournalAnnual Review of Pharmacology and Toxicology
Volume41
DOIs
StatePublished - May 10 2001
Externally publishedYes

Fingerprint

Tachykinin Receptors
Neurokinin-1 Receptors
Antidepressive Agents
Anti-Anxiety Agents
Substance P
Anxiety Disorders
Analgesics
Clinical Trials
Depression
Research
Pharmaceutical Preparations
Clinical Studies

Keywords

  • Antidepressant
  • Anxiolytic
  • MK-869
  • Neuropeptide
  • NK
  • Substance P

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Neurokinin1 receptor antagonists as potential antidepressants. / Stout, S. C.; Owens, M. J.; Nemeroff, Charles.

In: Annual Review of Pharmacology and Toxicology, Vol. 41, 10.05.2001, p. 877-906.

Research output: Contribution to journalArticle

@article{1f27a79990184361afc7d42a41c10107,
title = "Neurokinin1 receptor antagonists as potential antidepressants",
abstract = "Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin1 (NK1). Although originally studied as potential analgesic compounds, recent evidence suggests that NK1 receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct from all existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK1 receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK1 receptor antagonists have served as an impetus for much needed, basic research in this field.",
keywords = "Antidepressant, Anxiolytic, MK-869, Neuropeptide, NK, Substance P",
author = "Stout, {S. C.} and Owens, {M. J.} and Charles Nemeroff",
year = "2001",
month = "5",
day = "10",
doi = "10.1146/annurev.pharmtox.41.1.877",
language = "English",
volume = "41",
pages = "877--906",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0066-4251",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Neurokinin1 receptor antagonists as potential antidepressants

AU - Stout, S. C.

AU - Owens, M. J.

AU - Nemeroff, Charles

PY - 2001/5/10

Y1 - 2001/5/10

N2 - Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin1 (NK1). Although originally studied as potential analgesic compounds, recent evidence suggests that NK1 receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct from all existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK1 receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK1 receptor antagonists have served as an impetus for much needed, basic research in this field.

AB - Selective, nonpeptide antagonists for tachykinin receptors first became available ten years ago. Of the three known tachykinin receptors, drug development has focused most intensively on the substance P-preferring receptor, neurokinin1 (NK1). Although originally studied as potential analgesic compounds, recent evidence suggests that NK1 receptor antagonists may possess antidepressant and anxiolytic properties. If confirmed by further controlled clinical studies, this will represent a mechanism of action distinct from all existing antidepressant agents. As reviewed in this chapter, the existing preclinical and clinical literature is suggestive of, but not conclusive, concerning a role of substance P and NK1 receptors in the pathophysiology of depression and/or anxiety disorders. The ongoing clinical trials with NK1 receptor antagonists have served as an impetus for much needed, basic research in this field.

KW - Antidepressant

KW - Anxiolytic

KW - MK-869

KW - Neuropeptide

KW - NK

KW - Substance P

UR - http://www.scopus.com/inward/record.url?scp=0035042259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035042259&partnerID=8YFLogxK

U2 - 10.1146/annurev.pharmtox.41.1.877

DO - 10.1146/annurev.pharmtox.41.1.877

M3 - Article

C2 - 11264480

AN - SCOPUS:0035042259

VL - 41

SP - 877

EP - 906

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0066-4251

ER -